Evan S. Dellon, MD, MPH
Dupilumab decreased esophageal inflammation and may improve the ability of patients with eosinophilic esophagitis to swallow, according to results presented at the 2022 annual meeting of the American Academy of Allergy, Asthma, and Immunology.
On May 20, the FDA approved dupilumab (Dupixent, Sanofi/Regeneron) as a treatment for patients 12 years and older with EoE.
“These results are encouraging and showed dupilumab taken weekly not only improved patients’